Albany Molecular Research, Inc. (AMRI) Shares Sold by Prudential Financial Inc.

Albany Molecular Research, Inc. (AMRI) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. lowered its position in Albany Molecular Research, Inc. (NASDAQ:AMRI) by 39.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,640 shares of the company’s stock after selling 26,080 shares during the period. Prudential Financial Inc. owned approximately 0.11% of Albany Molecular Research worth $654,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of AMRI. Bank of Montreal Can bought a new stake in shares of Albany Molecular Research during the second quarter worth approximately $7,777,000. Loomis Sayles & Co. L P raised its stake in shares of Albany Molecular Research by 911.8% in the second quarter. Loomis Sayles & Co. L P now owns 638,667 shares of the company’s stock worth $8,584,000 after buying an additional 575,543 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Albany Molecular Research during the third quarter worth approximately $7,494,000. Emerald Advisers Inc. PA bought a new stake in shares of Albany Molecular Research during the third quarter worth approximately $6,830,000. Finally, Vaughan Nelson Investment Management L.P. raised its stake in shares of Albany Molecular Research by 9.0% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 1,940,375 shares of the company’s stock worth $32,035,000 after buying an additional 160,450 shares in the last quarter. 71.27% of the stock is currently owned by hedge funds and other institutional investors.

Albany Molecular Research, Inc. (NASDAQ:AMRI) opened at 18.27 on Friday. The company’s market cap is $759.85 million. The stock has a 50 day moving average of $18.31 and a 200 day moving average of $16.31. Albany Molecular Research, Inc. has a 52 week low of $12.45 and a 52 week high of $19.35.

Albany Molecular Research (NASDAQ:AMRI) last posted its earnings results on Tuesday, November 8th. The company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.04. Albany Molecular Research had a positive return on equity of 7.25% and a negative net margin of 10.48%. The company earned $151.70 million during the quarter, compared to the consensus estimate of $160.75 million. During the same quarter last year, the firm earned ($0.12) earnings per share. The company’s revenue was up 45.0% on a year-over-year basis. Equities research analysts predict that Albany Molecular Research, Inc. will post $1.08 earnings per share for the current fiscal year.

In related news, SVP Lori M. Henderson sold 6,000 shares of the business’s stock in a transaction dated Wednesday, November 16th. The stock was sold at an average price of $17.00, for a total value of $102,000.00. Following the completion of the transaction, the senior vice president now owns 51,337 shares of the company’s stock, valued at $872,729. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Steven R. Hagen sold 9,000 shares of the business’s stock in a transaction dated Wednesday, November 30th. The shares were sold at an average price of $16.71, for a total value of $150,390.00. Following the completion of the transaction, the senior vice president now directly owns 43,913 shares of the company’s stock, valued at approximately $733,786.23. The disclosure for this sale can be found here. Insiders have sold 15,785 shares of company stock valued at $265,570 in the last three months. Insiders own 17.50% of the company’s stock.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research, Inc. (NASDAQ:AMRI).

Related posts

Leave a Comment